22nd Century Group Inc (NYSEMKT:XXII) has today made a crucial announcement. The provider and Heracles Pharmaceuticals, which happens to be its wholly owned subsidiary on June 20, 2017, attended a meeting with the multi-discipline review team in the Division of Anesthesia, Analgesia, and Addiction Products. The meeting took place at the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) where the business of the day was to closely monitor the provider’s Investigational New Drug Application (IND).
22nd Century’s X-22 prescription-based smoking cessation product has been under development for over some time now and the various doctors will be able to access it. They will use it to help those patients addicted to smoking stop the habit upon prescription.
According to Yahoo.com, the meeting with the FDA/CDER has been termed by officials working with the drug manufacturer as positive and productive.22nd Century and FDA/CDER will be coming together to discuss the Company’s design and implementation of two parallel, Phase III clinical trials which will most probably be conducted by the provider in different areas of the United States. It will be a move seeking to showcase that indeed Company’s X-22 prescription-based smoking cessation product will be the most ideal product in the market towards helping patients quit the smoking habit.
As a matter of fact there are existing smoking cessation products in the markets today but they have not been indicating effectiveness in helping resolve the difficult problem. However, 22nd Century believes it has what it takes to face out the “nightmare” and sees its recent product as the solution that the world has been waiting for. The success of this product will help the provider achieve robust business success and of course the boosted revenues will lead to the implementation of better business strategies and business expansions.
President and Chief Executive Officer of 22nd Century Group, Henry Sicignano while recently addressing a press conference said that they looked forward to reducing harm caused by smoking. They were going to use their novel X-22 smoking cessation product in development.
